Showing results (91-100 of 453) with videos related to
Sort By:
Pageof 46
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.Plos Pathogens|May 24, 2021
Type I and III IFNs produced by the nasal epithelia and dimmed inflammation are features of alpacas resolving MERS-CoV infectionNigeer Te, Jordi Rodon, Maria Ballester, et al.Expert Opinion on Investigational Drugs|November 18, 2008
Reovirus therapy in cancer: has the orphan virus found a home?Timothy A Yap, Andre Brunetto, Hardev Pandha, et al.Expert Opinion on Drug Discovery|March 15, 2013
Targeting cell cycle kinases and kinesins in anticancer drug developmentTimothy A Yap, L Rhoda Molife, Sarah P Blagden, et al.Pharmacogenomics and Personalized Medicine|December 3, 2021
Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer MedicineNiamh Coleman, Justin T Moyers, Alice Harbery, et al.Science Translational Medicine|March 31, 2012
Intratumor heterogeneity: seeing the wood for the treesTimothy A Yap, Marco Gerlinger, P Andrew Futreal, et al.Nature Reviews. Cancer|June 11, 2010
Envisioning the future of early anticancer drug developmentTimothy A Yap, Shahneen K Sandhu, Paul Workman, et al.Trends in Pharmacological Sciences|November 23, 2016
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel TherapeuticsDearbhaile C Collins, Raghav Sundar, Joline S J Lim, et al.Current Opinion in Pharmacology|July 16, 2008
Targeting CYP17: established and novel approaches in prostate cancerTimothy A Yap, Craig P Carden, Gerhardt Attard, et al.Expert Opinion on Investigational Drugs|July 23, 2011
Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategiesTimothy A Yap, David Olmos, Lulama Rhoda Molife, et al.Pageof 46